Lilly has announced plans to invest at least $27 billion in the construction of four new manufacturing facilities in the U.S.

Pharmaceutical giant Eli Lilly & Co. has announced plans to invest at least $27 billion in the U.S. to build four new manufacturing facilities, bringing its total U.S. investment in recent years to over $50 billion, a record for the U.S. pharmaceutical industry. The investment is aimed at meeting the strong demand for its blockbuster weight loss drug Zepbound and diabetes drug Mounjaro, as well as supporting the development of new drugs for other diseases.

Three of the facilities will focus on producing active pharmaceutical ingredients, such as the key components of Zepbound and Mounjaro, tirzepatide, to alleviate supply chain shortages in the U.S. The fourth facility will expand the company's global manufacturing network for future injectable therapies.

The new investment is expected to create over 3,000 jobs and provide 10,000 construction jobs during the factory construction period.

In addition to Zepbound and Mounjaro, Lilly is confident in its pipeline in areas such as cardiovascular metabolism, oncology, immunology, and neuroscience, hoping to bring more breakthrough drugs to market, such as innovative therapies for cancer and Alzheimer's disease.

Currently, Lilly and Novo Nordisk are co-leading the rapidly growing GLP-1 drug market. Ensuring production capacity and supply chain stability is crucial as the global obesity drug market is expected to exceed $150 billion by the early 2030s, and the competition is becoming increasingly fierce.